Leukemia: cross-border specialty drug access for international patients
Hematologic oncology
ICD-10: C91-C95
Quick orientation
Leukemias collectively account for approximately 3 percent of all cancers globally. Acute and chronic forms, lymphoid and myeloid, differ substantially in epidemiology and treatment.
Typical age of onset. All ages; specific subtypes have characteristic age distributions. Pediatric ALL and adult CLL are common examples.
Severity tiers. Severity depends on subtype, cytogenetics, and molecular markers. Acute leukemias require urgent therapy; chronic forms may be observed.
Why specialty drugs for Leukemia are hard to access internationally
Targeted therapies and CAR-T cell products have transformed leukemia care but are difficult to access internationally. Newer FDA approvals such as bispecific T-cell engagers for ALL and BTK inhibitors with improved profiles for CLL are not yet broadly registered.
Treatments approved by the FDA
- Aucatzyl (obecabtagene autoleucel) — FDA approval: 2024. Mechanism: CD19-directed CAR-T cell therapy for relapsed/refractory adult B-ALL. Route: One-time intravenous infusion of autologous CAR-T cells. US WAC ballpark: Approximately USD 525,000 one-time. Country pricing: UAE · Saudi Arabia · India · Kuwait · Jordan.
- Jaypirca (pirtobrutinib) — FDA approval: 2023. Mechanism: Non-covalent BTK inhibitor. Route: Oral once daily. US WAC ballpark: Approximately USD 250,000 per year. Country pricing: Saudi Arabia · Kuwait · Egypt · Jordan · Bahrain.
- Revuforj (revumenib) — FDA approval: 2024. Mechanism: Menin inhibitor for KMT2A-rearranged or NPM1-mutated acute leukemia. Route: Oral twice daily. US WAC ballpark: Approximately USD 360,000 per year. Country pricing: UAE · Saudi Arabia · India · Egypt · Jordan.
- Rytelo (imetelstat) — FDA approval: 2024. Mechanism: Telomerase inhibitor (MDS label; relevant adjacent indication). Route: Intravenous infusion every 4 weeks. US WAC ballpark: Approximately USD 200,000 per year. Country pricing: Saudi Arabia · Egypt.
Cross-border pathways used for Leukemia
Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:
What your physician needs to know
- Confirm subtype, cytogenetics, and molecular profile.
- Document prior therapy and response.
- CAR-T products require qualified treatment centers.
- BTK and menin inhibitors require monitoring for differentiation syndrome and infection risk.
- Hematology-oncology co-management is essential.
Common questions
Can I receive CAR-T abroad?
CAR-T cell therapies are administered at qualified centers, primarily in the US and Europe. Reserve Meds supports medical-tourism access where appropriate.
Are oral targeted therapies available locally?
Older agents (e.g., imatinib, ibrutinib) are widely registered. Newer agents (e.g., pirtobrutinib, revumenib) have narrower footprints.
How long does shipment take?
Five to fifteen business days for oral products.
What documents are required?
Hematologist-oncologist's prescription, pathology with cytogenetics and molecular profile, and treatment history.
Who pays for CAR-T?
Reserve Meds operates cash-pay; many families combine personal funds with foundation support.
Where Reserve Meds fits in
Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Leukemia, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.
We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.
Start a request
Reserved for you.